<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526666</url>
  </required_header>
  <id_info>
    <org_study_id>17022</org_study_id>
    <nct_id>NCT03526666</nct_id>
  </id_info>
  <brief_title>Ascorbic Acid Levels in MDS, AML, and CMML Patients</brief_title>
  <official_title>Collection of Peripheral Blood From Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia for Measuring Baseline Ascorbic Acid Levels and Future Epigenetic Cancer Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Van Andel Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Van Andel Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a non-interventional, specimen collection translational study to evaluate
      vitamin C levels in the peripheral blood of Acute Myeloid Leukemia (AML), Myelodysplastic
      Syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our collaborators published that hematological cancer patients with myelodysplastic syndrome
      (MDS) or acute myeloid leukemia (AML) often exhibit severe vitamin C deficiency. Their study
      analyzed specimens from a cohort of patients in Copenhagen. We aim to determine if those
      results are conserved in another population/geographical location.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral blood ascorbic acid levels</measure>
    <time_frame>1 year</time_frame>
    <description>The level of ascorbic acid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of human endogenous retroviral sequences (HERVs) expression</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of 5-methylcitosine (5-mC) and 5-hydroxymethylcytosine (5-hmC) levels</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>MDS</condition>
  <condition>AML</condition>
  <condition>CMML</condition>
  <arm_group>
    <arm_group_label>AML, MDS, and CMML patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peripheral blood collection</intervention_name>
    <description>Peripheral blood collection for the measurement of ascorbic acid levels and banking of plasma and buffy coat for future resrearch.</description>
    <arm_group_label>AML, MDS, and CMML patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. Plasma with ascorbic acid redox analysis prep (additive: MPA solution, 10 %
           meta-phosphoric acid w/v containing 2 mM Na2EDTA)

        2. Plasma

        3. Buffy coat pellet
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients seen in hematology/oncology clinics in Grand Rapids, MI
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients actively receiving treatment for acute myeloid leukemia (AML),
             myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).

          -  Patients diagnosed with AML, MDS, or CMML and are treatment naïve.

          -  Patients who are 18 years old or older.

        Exclusion Criteria:

          -  Patients deemed as too ill to participate as determined by the clinical investigator.

          -  Non-English speaking patients

          -  Patients unable to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dan Rogers, CCRC, CIP</last_name>
    <phone>616-234-5457</phone>
    <email>dan.rogers@vai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ryan Burgos, BS</last_name>
    <phone>616-234-5483</phone>
    <email>ryan.burgos@vai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer and Hematology Centers of Western Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny Berger</last_name>
      <phone>616-954-5550</phone>
      <phone_ext>2041</phone_ext>
      <email>pberger@chcwm.com</email>
    </contact>
    <investigator>
      <last_name>Brett Brinker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Health - University of Michigan Health</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Door, BSN, RN, OCN</last_name>
      <phone>616-252-5127</phone>
      <email>amber.door@metrogr.org</email>
    </contact>
    <investigator>
      <last_name>Michael Zakem, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Dublis, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gillberg L, Ørskov AD, Liu M, Harsløf LBS, Jones PA, Grønbæk K. Vitamin C - A new player in regulation of the cancer epigenome. Semin Cancer Biol. 2017 Nov 2. pii: S1044-579X(17)30189-X. doi: 10.1016/j.semcancer.2017.11.001. [Epub ahead of print] Review.</citation>
    <PMID>29102482</PMID>
  </reference>
  <reference>
    <citation>Liu M, Ohtani H, Zhou W, Ørskov AD, Charlet J, Zhang YW, Shen H, Baylin SB, Liang G, Grønbæk K, Jones PA. Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine. Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10238-44. doi: 10.1073/pnas.1612262113. Epub 2016 Aug 29.</citation>
    <PMID>27573823</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Van Andel Research Institute</investigator_affiliation>
    <investigator_full_name>Peter Jones</investigator_full_name>
    <investigator_title>Cheif Scientific Officer</investigator_title>
  </responsible_party>
  <keyword>Vitamin C</keyword>
  <keyword>Ascorbic Acid</keyword>
  <keyword>Epigenetics</keyword>
  <keyword>5-hydroxymethylcytosine</keyword>
  <keyword>5-methylcytosine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

